Pfizer- BioNTech’s covid-19 vaccine to be approved by November

Vaccine development for Covid-19 is being developed at brisk pace, where a cut throat competition of companies involving Oxford- Astrazeneca, the Moderna vaccine and Russian’s Sputnik V are in the list.

Every now and then the latest developments have raised the expectations of the people who have been eagerly waiting. Reports now suggest that, leading pharmaceutical giant Pfizer is no way lesser in this race and is likely to steal the top spot.

The inoculation being developed by Pfizer and BioNTech SE is presently on track to be submitted for review by regulatory body FDA and institution ethics committee as early as October, after assessing the data from early-stage study.

Recent study states, the vaccine was proven to be effective with mild to moderate fever in less than 20 percent of the participants. Researchers are still determining the data reported from Phase I trials in the US, and Germany, Pfizer & BioNTech.

The vaccine which Pfizer and BioNTech are studying on, is empirically a single nucleoside-modified messenger RNA (modRNA) based vaccine dubbed BNT162. Experts claim that Pfizer’s vaccine is one of the fastest moving in the world, which could even be approved very soon by November.